drugset / Trial / NCT00649129
Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to investigate the single-dose relative bioavailability of Mylan's oxybutynin chloride extended-release tablets to ALZA's Ditropan XL® tablets following an oral, single 20 mg (2 x 10 mg) dose under fasting conditions.
Timeline
- Start
- 2002-07
- Primary completion
- 2002-08
- Completion
- 2002-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxybutynin | Small molecule | 20 mg | Oral |
Indications
No indication recorded.